CN103599135B - A kind of Tiny ecosystem solid pharmaceutical preparation treating alcoholic liver injury and preparation method thereof - Google Patents
A kind of Tiny ecosystem solid pharmaceutical preparation treating alcoholic liver injury and preparation method thereof Download PDFInfo
- Publication number
- CN103599135B CN103599135B CN201310526031.6A CN201310526031A CN103599135B CN 103599135 B CN103599135 B CN 103599135B CN 201310526031 A CN201310526031 A CN 201310526031A CN 103599135 B CN103599135 B CN 103599135B
- Authority
- CN
- China
- Prior art keywords
- preparation
- liver injury
- alcoholic liver
- tiny ecosystem
- solid pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses the preparation method of a kind of Tiny ecosystem solid pharmaceutical preparation for treating alcoholic liver injury, by bifidobacterium longum NQ 1501 bacterial strain is made bacterium powder, and bacterium powder and auxiliary material are mixed and made into preparation, said preparation can reach treat alcoholic liver injury and adjust the effect of gut flora, effectively alleviates the alcohol injury to human body.
Description
Technical field
The invention belongs to biological pharmacy technical field, be specifically related to a kind of alcoholic liver injury and regulating intestinal canal flora of can treating
Tiny ecosystem solid pharmaceutical preparation and preparation method thereof.
Background technology
Worldwide, alcohol to oil ratio is in rising trend per capita, the public affairs that the various problems caused of drinking have become more serious
One of hygienic issues altogether.According to investigations, the death rate of chronic alcoholism person is higher than general resident 1-3 times.At the countries such as America and Europe, alcohol
Property hepatopathy be one of young and middle-aged main causes of death, the U.S. dies from Alcohol-Related Disorders every year, and person reaches 8.5 ten thousand people.Liver is
One of organ that body weight for humans is wanted, has extremely important effect in metabolism.After ethanol enters human liver cell, through three kinds of enzyme system ways
Footpath is oxidized to acetaldehyde.Excessive consumption of alcohol, a large amount of acetaldehyde have obvious toxic action, thus directly or indirectly cause liver liver cell
Damage.
Being covered with quantity in the stomach and intestine of people and reached the bacterium of 10,000,000,000,000, be ten times of human body cell, wherein more than 80% is all to human body
Useful, these beneficial bacteriums can stick on intestinal mucosa, becomes one protective barrier, referred to as mycoderm barrier for people's bodily form.And wine
Being a kind of irritating material, they can make enteron aisle lose mycoderm protection, and enterogenous endotoxin and harmful bacteria will corrode gastrointestinal mucosa,
Cause various gastrointestinal disease.
Therefore, excessive consumption of alcohol can cause various digestive discomfort even pathology, in addition to alcohol is to the stimulation of gastrointestinal mucosa, the most former
Cause is that stomach flora is unbalance in fact.
The research relatively morning to this aspect abroad.Adawi in 1997 etc. utilize lactobacillus reuteri R2LC, Lactobacillus rhamnosus
DSM6594, lactobacillus fermenti 8704:3, lactobacillus reuteri 108, Lactobacillus plantarum DSM9843+ arginine feeding liver
The mouse of damage, found that Lactobacillus plantarum DSM9843+ arginine group can reduce liver organized enzyme (total bilirubin, alkalescence
Phosphatase, alanine aminotransferase, aspartate aminotransferase) burst size.2009, according to the northern medical courses in general of Russia
University and the research report of medical college of University of Louisville of the U.S., short-term supplements bifidobacterium bifidum and Lactobacillus plantarum 8PA3
The intestinal health of great drinker can be improved.Probio has potential health effect to great drinker, potentially contributes to improve liver enzyme
Activity.
Deepen further on the basis of domestic research abroad.The Duan Zhong of Beijing artificial liver in treatment training center of You An hospital in 2005
Flat interest zoopery demonstrates gastric mucosa and the protective effect of hepar damnification that alcohol is caused by lactic acid bacteria.Yangzhou University in 2007
Xiao Lixia etc. utilize zoopery to confirm the liver protection function after drinking of lactic acid bacteria.The Wang Huijing of Yangzhou University in 2008 is to sieve
Choosing obtains 3 strains (the green bar of S.thermophilus GP1, E.faecium ST1, L.rhamnosus) and has the lactic acid of antioxidation activity
Bacterium is verified with acute alcohol hepatic injury mouse, and lactic acid bacteria shows the feature of protection hepar damnification.
Have correlation technique, CN201110432768.2, CN201210005581.9, above patented technology the most at home
Relating to a kind of liquid beverage, its shortcoming is that the probio time-to-live in a liquid is shorter.It is compound that above patented technology uses
Bacterial classification increases production cost, and effect is general.The present invention can overcome the shortcoming of above technology, not only time-to-live length and also controlling
Can be with regulating intestinal canal flora while treating alcoholic liver injury.
Summary of the invention
It is an object of the present invention to provide the preparation of a kind of Tiny ecosystem solid pharmaceutical preparation that can treat alcoholic liver injury and regulating intestinal canal flora
Method, comprises the following steps:
(1) bifidobacterium longum NQ-1501 is through Anaerobic culturel in its fermentation medium, and fermentation temperature is 40 DEG C, when most preferably fermenting
Between be 8h；
Wherein fermentative medium formula is: 1.2% lactose, 0.8% beef extract, 0.4% triammonium citrate, 0.4% potassium acetate, 0.04%
Magnesium sulfate, 0.05%L-cysteine hydrochloride, 0.08% Tween-80, water is added by the amount of required culture medium；
(2) being centrifuged 30 minutes by gained zymotic fluid 15000g, abandoning supernatant, obtain wet bacterium mud, add protective agent, stirring is all
Even, pour in freeze dryer lyophilized, obtain white powder bacterium powder；
The most protectant formula is: add 20ml60% skimmed milk power, 5ml5% starch in 300ml system；
(3) bifidobacterium longum NQ-1501 bacterium powder is mixed according to the ratio of 1:9 with supplementary product starch, make preparation.
In a concrete technical scheme of the present invention, by bifidobacterium longum NQ-1501 bacterium powder and supplementary product starch, according to 1:9's
Ratio is sufficiently mixed, and is pressed into the tablet that two sides is flat, average tablet weight 0.4g with tablet press machine, and tablet 1g weight, viable count is 200
About hundred million, the consumption of adult be 1 day 2, within 30th, be 1 course for the treatment of.
In a concrete technical scheme of the present invention, by bifidobacterium longum NQ-1501 bacterium powder and supplementary product starch, according to 1:9's
Ratio is sufficiently mixed, and is contained in the capsule in the cylindric glue shell made with gelatin for primary raw material, and capsule volume is 0.48ml, and 1
Capsule volume viable count is about 20,000,000,000, the consumption of adult be 1 day 2, within 30th, be 1 course for the treatment of.
In a concrete technical scheme of the present invention, by bifidobacterium longum NQ-1501 bacterium powder and supplementary product starch, according to 1:9's
Ratio is sufficiently mixed, the powder powder made, and is contained in aluminium plastic bag, every bag of 1g, and viable count is about 20,000,000,000, adult
Consumption be 2g on the 1st, within 30th, be 1 course for the treatment of.
It is a further object to provide a kind of Tiny ecosystem solid pharmaceutical preparation that can treat alcoholic liver injury, said preparation also may be used
With regulating intestinal canal flora.
Another object of the present invention is to provide aforementioned Tiny ecosystem solid pharmaceutical preparation in the medicine of preparation treatment alcoholic liver injury
Application.
Another object of the present invention is to provide bifidobacterium longum NQ-1501 answering in the medicine preparing alcoholic liver injury
With.
Owing to have employed above-mentioned preparation method, the invention has the beneficial effects as follows:
1, bifidobacterium longum NQ-1501 bacterial strain function admirable, the fermentation used time is short, and lyophilized stability is preferable, and bacterium powder viable count is relatively
Many and nontoxic, antagonistic effect is obvious, regulating intestinal canal flora while treatment alcoholic liver injury, and effect is obvious；
2, preparation method is practical, simple to operate, the cycle is short, step is easy rationally, has low cost, productivity high, suitable
The advantages such as large-scale production.
Detailed description of the invention
The production technology of embodiment 1. bifidobacterium longum NQ-1501 bacterial strain bacterium powder
Choose the bifidobacterium longum NQ-1501 bacterial strain unique bacterial strain as preparation of Shuan Qi company.
The Optimal compositions of fermentation medium of bifidobacterium longum NQ-1501 bacterial strain: 1.2% lactose, 0.8% beef extract, 0.4% triammonium citrate,
0.4% potassium acetate, 0.04% magnesium sulfate, 0.05%L-cysteine hydrochloride, 0.08% Tween-80.
Bifidobacterium longum NQ-1501 is through Anaerobic culturel in its fermentation medium, and fermentation temperature is 40 DEG C, and optimal fermentation time is
8h.Gained zymotic fluid 15000g is centrifuged 30 minutes, abandoning supernatant, obtains wet bacterium mud, add protective agent, stir,
Pour in freeze dryer lyophilized, obtain white powder bacterium powder.Protectant formula is: add 20ml60% in 300ml system
Skimmed milk power, 5ml5% starch.
Embodiment 2. treats the making of the Tiny ecosystem solid pharmaceutical preparation of alcoholic liver injury
By bifidobacterium longum NQ-1501 bacterium powder and supplementary product starch, be sufficiently mixed according to the ratio of 1:9, make tablet, capsule and
Powder.
A, by bifidobacterium longum NQ-1501 bacterium powder and supplementary product starch, be sufficiently mixed according to the ratio of 1:9, be pressed into tablet press machine
The tablet that two sides is flat, average tablet weight 0.4g, tablet 1g weight, viable count is about 20,000,000,000, and the consumption of adult is 1 day 2
Sheet, 30th was 1 course for the treatment of.
B, by bifidobacterium longum NQ-1501 bacterium powder and supplementary product starch, be sufficiently mixed according to the ratio of 1:9, be contained in based on gelatin
Wanting in the capsule in the cylindric glue shell that raw material makes, capsule volume is 0.48ml, and 1 capsule volume viable count is about 20,000,000,000,
The consumption of adult be 1 day 2, within 30th, be 1 course for the treatment of.
C, by bifidobacterium longum NQ-1501 bacterium powder and supplementary product starch, be sufficiently mixed according to the ratio of 1:9, the powder made dissipate
Agent, is contained in aluminium plastic bag, every bag of 1g, and viable count is about 20,000,000,000, and the consumption of adult is 2g on the 1st, within 30th, is 1 treatment
Journey.
Embodiment 3. treats the liver protecting characteristic of the Tiny ecosystem solid pharmaceutical preparation of alcoholic liver injury
One, experiment material:
1. experimental preparation:
The Tiny ecosystem solid pharmaceutical preparation of the treatment alcoholic liver injury containing bifidobacterium longum NQ-1501, by the double strange medicine company share in the Inner Mongol
Co., Ltd provides.
2. animal used as test:
Adult Wistar male mouse, body weight 18 ± 22 grams, University of the Inner Mongol's animal experimental center provide.
3. experiment kit:
Triglycerides (TG enzyme process) testing cassete, VLDL (VLDL) ELISA kit in serum.
Two, experimental technique:
Mouse being randomly divided into 5 groups, i.e. blank group, model group, given the test agent group, given the test agent group is divided into again height
(90mg/kg.BW) (45mg/kg.BW), low (22.5mg/kg.BW) dosage group, often group 10 in,.Every day, per os gavage gave
Given the test agent, blank group and model group give pure water.Mouse is weighed weekly twice, adjusts given the test agent amount by body weight.
Model group and each sample group gavage at the end of experiment gives the ethanol of 50%, and blank group gives pure water, fasting 16h.
Eyeball blood sampling is plucked after the Nembutal sodium solution anesthesia of mouse peritoneal injection 60mg/kg BW.According to " health food laws and regulations "
In relevant regulations, measure the triglycerides (TG) in animal blood serum, serum VLDL (VLDL) two indices,
I.e. can determine whether whether product has protective effect to alcoholic liver injury.
Three, result and analysis:
The impact on mouse liver functional parameter of the Tiny ecosystem solid pharmaceutical preparation of table 1 alcoholic liver injury
Note: contrast with blank groupaP < 0.05, contrasts with model groupbp<0.05。
Four, conclusion:
Result shows: said preparation has therapeutic action to alcoholic liver injury.
Embodiment 4, the regulating intestinal canal flora characteristic of Tiny ecosystem solid pharmaceutical preparation for the treatment of alcoholic liver injury
One, experiment material:
1. experimental preparation:
The Tiny ecosystem solid pharmaceutical preparation of the treatment alcoholic liver injury containing bifidobacterium longum NQ-1501, by the double strange medicine company share in the Inner Mongol
Co., Ltd provides.
2. animal used as test:
Adult Wistar male mouse, body weight 18 ± 22 grams, University of the Inner Mongol's animal experimental center provide.
Two, experimental technique:
Mention collection fresh excreta 0.1g under mousetail gnotobasis, be loaded in the band bead EP pipe of prior sterilizing, add life
Reason salt solution 0.9mL, this is dilution factor 10 1, immediately by EP channel closure.Vibrate on oscillator 5min, makes ight soil homogeneous
Change.Sample good for above-mentioned vibration is carried out 10 times of serial dilutions to 10-5.With 1mL syringe and sterilizing suction nozzle, from highly diluted
Spend to low dilution factor each dropping dilution 50 μ L on corresponding culture medium, it is coated with on culture medium uniformly.Enterobacteria: she
Red methylene blue culture medium, 37 DEG C of aerobic cultivation 24h.Enterococcus: Sodium azide crystal violet esculin medium, 37 DEG C of aerobic cultivation 48h.
Lactobacillus: LBS culture medium, 37 DEG C of Anaerobic culturel 48h.Bifidobacterium: BBL culture medium, 37 DEG C of Anaerobic culturel 48h.Treat bacterium
Fall after growing, identify required purpose bacterium with colonial morphology, Grain stain, biochemical reaction.
Three, result and analysis:
The impact on mouse intestinal flora of the Tiny ecosystem solid pharmaceutical preparation of table 2 alcoholic liver injury
Note: contrast with blank groupaP < 0.05, contrasts with model groupbp<0.05。
Four, conclusion:
Said preparation can regulate the gut flora of feeding absolute ethyl alcohol mouse.
Above example is the preferred embodiments of the present invention, and what above example was summarized describes the present invention, can be by referring to this
Some specific embodiment that literary composition provides is further appreciated by the present invention, and these embodiments are merely to illustrate and not limit the present invention.
Claims (4)
1. the Tiny ecosystem solid pharmaceutical preparation application in the medicine of preparation treatment alcoholic liver injury, it is characterised in that Tiny ecosystem is solid
Body preparation is prepared by the following method:
(1) bifidobacterium longum NQ-1501 is through Anaerobic culturel in its fermentation medium, and fermentation temperature is 40 DEG C, when most preferably fermenting
Between be 8h；
Wherein fermentative medium formula is: 1.2% lactose, 0.8% beef extract, 0.4% triammonium citrate, 0.4% potassium acetate, 0.04%
Magnesium sulfate, 0.05%L-cysteine hydrochloride, 0.08% Tween-80, water is added by the amount of required culture medium；
(2) being centrifuged 30 minutes by gained zymotic fluid 15000g, abandoning supernatant, obtain wet bacterium mud, add protective agent, stirring is all
Even, pour in freeze dryer lyophilized, obtain white powder bacterium powder；
The most protectant formula is: add 20ml60% skimmed milk power, 5ml5% starch in 300ml system；
(3) bifidobacterium longum NQ-1501 bacterium powder is mixed according to the ratio of 1:9 with supplementary product starch, make preparation.
The application of Tiny ecosystem solid pharmaceutical preparation the most according to claim 1, wherein said dosage form is tablet, capsule or dissipates
Agent.
3. the Tiny ecosystem solid pharmaceutical preparation described in claim 1 is at preparation treatment alcoholic liver injury and the medicine of regulating intestinal canal flora
In application.
4. bifidobacterium longum NQ-1501 application in the medicine of preparation treatment alcoholic liver injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310526031.6A CN103599135B (en) | 2013-10-30 | 2013-10-30 | A kind of Tiny ecosystem solid pharmaceutical preparation treating alcoholic liver injury and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310526031.6A CN103599135B (en) | 2013-10-30 | 2013-10-30 | A kind of Tiny ecosystem solid pharmaceutical preparation treating alcoholic liver injury and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599135A CN103599135A (en) | 2014-02-26 |
| CN103599135B true CN103599135B (en) | 2016-08-24 |
Family
ID=50117442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310526031.6A Active CN103599135B (en) | 2013-10-30 | 2013-10-30 | A kind of Tiny ecosystem solid pharmaceutical preparation treating alcoholic liver injury and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599135B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111955727B (en) * | 2020-08-21 | 2022-08-09 | 华熙生物科技股份有限公司 | Application of tetrahydropyrimidines and drinking wine containing tetrahydropyrimidines |
| CN112458015B (en) * | 2020-11-27 | 2021-11-19 | 石家庄君乐宝乳业有限公司 | Bifidobacterium longum subspecies longum i772, and separation and purification method and application thereof |
| CN112807328B (en) * | 2021-02-26 | 2023-04-11 | 江苏德禧生物科技有限公司 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006713A (en) * | 2012-12-11 | 2013-04-03 | 内蒙古双奇药业股份有限公司 | Preparation method of microecological agent capable of reducing human body serum cholesterol content |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004277296A (en) * | 2003-03-13 | 2004-10-07 | Morishita Jintan Kk | Lactic acid bacterium-containing enteric pharmaceutical preparation |
| KR100661032B1 (en) * | 2005-04-19 | 2006-12-22 | 주식회사한국야쿠르트 | Composition for Improving Liver Function, Reduction of Serum Ethanol Level, and Antioxidation |
| CN101711582B (en) * | 2009-08-28 | 2012-08-22 | 上海交大昂立股份有限公司 | Composition containing American ginseng extract and probiotics and application thereof |
-
2013
- 2013-10-30 CN CN201310526031.6A patent/CN103599135B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006713A (en) * | 2012-12-11 | 2013-04-03 | 内蒙古双奇药业股份有限公司 | Preparation method of microecological agent capable of reducing human body serum cholesterol content |
Non-Patent Citations (1)
| Title |
|---|
| "Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.";Loguercio C, et al.;《J Clin Gastroenterol》;20050630;第39卷(第6期);摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599135A (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4163276B2 (en) | Functional composition | |
| KR101040721B1 (en) | Composition for alleviation of alcohol-induced hangover comprising Hovenia dulcis Thunberg contained Ssangwhatang | |
| TW200944215A (en) | Lactobacillus isolates having anti-inflammatory activities and uses of the same | |
| WO2011114645A1 (en) | Anti-allergic composition | |
| BR112012008005B1 (en) | composition comprising strains of lactobacillus plantarum | |
| MX2012009945A (en) | Lactic acid bacterium-containing preparation. | |
| CN110218681A (en) | One plant of lactobacillus fermenti KP101 and its application | |
| JP2007284360A (en) | Composition for activating ppar-dependent gene transcription, originated from lactobacillus | |
| CN103908585A (en) | Probiotic fermentation composition used for preventing and treating constipation | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| CN103446552B (en) | For the fermentation composition of prevention and therapy digestive system disease | |
| TWI627959B (en) | Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual | |
| TW201130496A (en) | Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application | |
| CN103599135B (en) | A kind of Tiny ecosystem solid pharmaceutical preparation treating alcoholic liver injury and preparation method thereof | |
| JP6990303B2 (en) | MEGAMONAS FUNIFORMIS and its applications | |
| JP5671358B2 (en) | Constipation improving agent | |
| JP2007082403A (en) | Food and drink containing complex composition comprising yucca extract, quillaia extract and lactobacillus, and method for producing the same | |
| JP2005013211A (en) | Lactobacillus-containing food composition | |
| TWI426915B (en) | Use of djulis in manufacturing of drugs for treating hyperlipidemia and hypercholesterolemia and a composition thereof | |
| KR100988923B1 (en) | Composition for alleviation of alcohol-induced hangover comprising lactic acid bacteria fermented Ssangwhatang | |
| TWI568368B (en) | Lactobacillus paracasei K71 | |
| CN103918795A (en) | Tea polyphenols probiotics goat milk tablet and preparation method thereof | |
| JP2001224330A (en) | Food comprising lactobacillus symbiotic culture product and medicinal plant and method for producing the same | |
| JP2010280602A (en) | Antiallergic composition | |
| JP7344661B2 (en) | Method for producing food composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |